Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Recent randomized trials have compared the newer antidiabetic agents to treatments involving sulfonylureas, drugs associated with increased cardiovascular risks and mortality in some observational studies with conflicting results. We reviewed the methodology of these observational studies by searching MEDLINE from inception to December 2015 for all studies of the association between sulfonylureas and cardiovascular events or mortality. Each study was appraised with respect to the comparator, the outcome, and study design–related sources of bias. A meta-regression analysis was used to evaluate heterogeneity. A total of 19 studies were identified, of which six had no major design-related biases. Sulfonylureas were associated with an increased risk of cardiovascular events and mortality in five of these studies (relative risks 1.16–1.55). Overall, the 19 studies resulted in 36 relative risks as some studies assessed multiple outcomes or comparators. Of the 36 analyses, metformin was the comparator in 27 (75%) and death was the outcome in 24 (67%). The relative risk was higher by 13% when the comparator was metformin, by 20% when death was the outcome, and by 7% when the studies had design-related biases. The lowest predicted relative risk was for studies with no major bias, comparator other than metformin, and cardiovascular outcome (1.06 [95% CI 0.92–1.23]), whereas the highest was for studies with bias, metformin comparator, and mortality outcome (1.53 [95% CI 1.43–1.65]). In summary, sulfonylureas were associated with an increased risk of cardiovascular events and mortality in the majority of studies with no major design-related biases. Among studies with important biases, the association varied significantly with respect to the comparator, the outcome, and the type of bias. With the introduction of new antidiabetic drugs, the use of appropriate design and analytical tools will provide their more accurate cardiovascular safety assessment in the real-world setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, sulfonylureas which are the second most commonly used antidiabetic drug after metformin, have been shown to be associated with an increased risk of cardiovascular events and mortality [71].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [71]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“For instance, using as comparator thiazolidinediones, which have been associated with an increased risk of cardiovascular events (55), could lead to an underestimation of the association.”
MethodSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708 · cited 1×
“ple, the 1,443 patients excluded because they received insulin some time during follow-up had to be alive at the time that they received the insulin; such exclusions will introduce immortal time bias (56).”
BackgroundSelf-citationHuxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534 · cited 1×
“It is well established that type 2 diabetes is associated with an increased risk of cardiovascular morbidity and mortality (1).”
BackgroundOral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108 · cited 1×
“In addition to the methodological issues described above, it is important to recognize that there are differences in the pharmacodynamic and pharmacokinetic properties of the different sulfonylureas; these may have an impact on their association with cardiovascular outcomes (58).”
Background(1970) · PubMed · Cited by 976
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531 · cited 4×
“In addition to its large sample size, this study restricted the cohort to patients newly treated with these drugs (defined as no prescription in the year before), thereby minimizing time-lag bias (53).”
BackgroundInfluentialSelf-citationHuang, E. S., Laiteerapong, N., Liu, J. Y., John, P. M., Moffet, H. H., & Karter, A. J. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12956 · Cited by 501 · cited 1×
“As duration of diabetes has been previously associated with cardiovascular outcomes (54), comparing drugs prescribed at different stages”
BackgroundTzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444 · cited 2×
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundImproved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419
Schramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Fosbøl, E. L., Køber, L., Norgaard, M. L., Madsen, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr077 · Cited by 418 · cited 1×
“To date, six observational studiesdidnot suffer fromthemajorbiases discussed above (11,21,29,38,43,46).”
BackgroundPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398 · cited 1×
“Indeed, sulfonylureas have been associated with weight gain, fluid retention, and hypoglycemia,which are all known cardiovascular risk factors (3).”
BackgroundBannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundGarratt, K. N., Brady, P. A., Hassinger, N. L., Grill, D. E., Terzic, A., & Holmes, D. R. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00557-9 · Cited by 332
Roumie, C. L., Hung, A. M., Greevy, R. A., Grijalva, C. G., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00003 · Cited by 300 · cited 2×
“(43), the authors used the Veterans Health Administration databases to assess whether sulfonylurea monotherapy (n =”
BackgroundCardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300
Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0176-9 · Cited by 293 · cited 2×
“comes, this exposure misclassification was magnified by using intent-to-treat (ITT) analyses (17,36,42).”
BackgroundMethodSimpson, S. H. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050748 · Cited by 235 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundCurrie, C. J., Poole, C. D., Evans, M., Peters, J. R., & Morgan, C. L. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3042 · Cited by 203 · cited 2×
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundA multicenter observational study of incretin-based drugs and heart failure
Filion, K. B., Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506115 · Cited by 196
Self-citationJohnson, J. A., Simpson, S. H., Toth, E. L., & Majumdar, S. R. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01448.x · Cited by 161
Andersson, C., Olesen, J. B., Hansen, P. R., Weeke, P. E., Norgaard, M. L., Jørgensen, C. H., Lange, T., Abildstrom, S. Z., Schramm, T. K., Vaag, A. A., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1906-6 · Cited by 159
MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S., Jhund, P. S., Petrie, M. C., McMurray, J. J. V., Petrie, J. R., & McAlister, F. A. (2010) · Diabetes Care · doi:10.2337/dc09-2227 · Cited by 149
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143
Bain, S., Druyts, E., Balijepalli, C., Baxter, C. A., Currie, C. J., Das, R., Donnelly, R., Khunti, K., Langerman, H., Leigh, P., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12821 · Cited by 142
Zeller, M., Danchin, N., Simon, D., Vahanian, A. S., Lorgis, L., Cottin, Y., Berland, J., Guéret, P., Wyart, P., Deturck, R., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0449 · Cited by 132
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0090-3 · Cited by 123 · cited 2×
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundSitagliptin Use in Patients With Diabetes and Heart Failure
Weir, D. L., McAlister, F. A., Senthilselvan, A., Minhas‐Sandhu, J. K., & Eurich, D. T. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.04.005 · Cited by 122 · cited 1×
“(64–72), with the exception of two studies (73,74).”
BackgroundOlsson, J., Lindberg, G., Gottsäter, M., Lindwall, K., Sjöstrand, Å., Tisell, A., & Melander, A. (2000) · Diabetologia · doi:10.1007/s001250051343 · Cited by 122 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundCoronary heart disease outcomes in patients receiving antidiabetic agents
McAfee, A. T., Koro, C., Landon, J., Ziyadeh, N., & Walker, A. M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1443 · Cited by 109 · cited 1×
“To date, six observational studiesdidnot suffer fromthemajorbiases discussed above (11,21,29,38,43,46).”
BackgroundEffect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus
Evans, J. M. M., Doney, A. S. F., AlZadjali, M. A., Ogston, S. A., Petrie, J. R., Morris, A. D., Struthers, A. D., Wong, A., & Lang, C. C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.031 · Cited by 107
The Risk of Heart Failure in Patients with Type 2 Diabetes Treated with Oral Agent Monotherapy
McAlister, F. A., Eurich, D. T., Majumdar, S. R., & Johnson, J. A. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.05.013 · Cited by 107 · cited 1×
“The aforementioned studies were classified into one of four categories: exposure misclassification (17,36,42), time-lag bias (12,13,20,25,26,37,42,45,48), selectionbias (14,22), and studieswithnomajor”
BackgroundOu, S., Shih, C.-J., Chao, P.-W., Chu, H., Kuo, S., Lee, Y.-J., Wang, S., Yang, C., Lin, C., Chen, T., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0308 · Cited by 106
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01604.x · Cited by 100 · cited 3×
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundMethodVariations in tissue selectivity amongst insulin secretagogues: a systematic review
Abdelmoneim, A. S., Hasenbank, S., Seubert, J. M., Brocks, D. R., Light, P. E., & Simpson, S. H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01496.x · Cited by 92 · cited 1×
“Indeed, some sulfonylureas are not selective for pancreatic b-cells and thus may increase the risk of cardiovascular outcomesbybinding to receptors in other tissues, such as cardiomyocytes and vascular smooth muscle cells (59).”
BackgroundToh, S., Hampp, C., Reichman, M. E., Graham, D. J., Balakrishnan, S., Pucino, F., Hamilton, J., Lendle, S., Iyer, A., Rucker, M., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2568 · Cited by 91
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2010) · Diabetes Care · doi:10.2337/dc10-0017 · Cited by 86 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundFu, A. Z., Johnston, S. S., Ghannam, A. F., Tsai, K., Cappell, K. A., Fowler, R., Riehle, E., Cole, A. L., Kalsekar, I. D., & Sheehan, J. J. (2016) · Diabetes Care · doi:10.2337/dc15-0764 · Cited by 81
Klamann, A. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1999 · Cited by 80
Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs
Johnsen, S. P., Monster, T. B. M., Olsen, M. L., Horsdal, H. T., McLaughlin, J. K., Sørensen, H. T., Lervang, H.-H., & Rungby, J. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200603000-00009 · Cited by 78 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundGulliford, M. C., & Latinovic, R. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.457 · Cited by 67 · cited 2×
“To date, six observational studiesdidnot suffer fromthemajorbiases discussed above (11,21,29,38,43,46).”
BackgroundSitagliptin and the risk of hospitalization for heart failure: A population-based study
Wang, K.-L., Liu, C., Chao, T., Huang, C.-M., Wu, C., Chen, S., Yeh, C., Chen, T., Lin, S., & Chiang, C. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.038 · Cited by 64 · cited 1×
“(64–72), with the exception of two studies (73,74).”
BackgroundKahler, K. H., Rajan, M., Rhoads, G. G., Safford, M. M., Demissie, K., Lu, S., & POGACH, L. M. (2007) · Diabetes Care · doi:10.2337/dc06-2272 · Cited by 61
All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides
Mannucci, E., Monami, M., Masotti, G., & Marchionni, N. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.411 · Cited by 60 · cited 3×
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundGenuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60 · cited 1×
“This may be related to the fact that sulfonylureas have a lower efficacy in lowering HbA1c than metformin (52).”
BackgroundJørgensen, C. H., Gislason, G. H., Andersson, C., Ahlehoff, O., Charlot, M., Schramm, T. K., Vaag, A., Abildstrøm, S. Z., Torp-Pedersen, C., & Hansen, P. R. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-54 · Cited by 60
Wheeler, S., Moore, K. P., Forsberg, C. W., Riley, K., Floyd, J. S., Smith, N. L., & Boyko, E. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2958-1 · Cited by 57
Khalangot, M. D., Tronko, M. D., Kravchenko, V. I., & Kovtun, V. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.008 · Cited by 56 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundIncretin-Based Drugs and the Risk of Congestive Heart Failure
Yu, O. H. Y., Filion, K. B., Azoulay, L., Patenaude, V., Majdan, A., & Suissa, S. (2014) · Diabetes Care · doi:10.2337/dc14-1459 · Cited by 53
Self-citationChen, D., Wang, S.-H., Mao, C., Tsai, M., Lin, Y., Chou, C., Wen, M., Wang, C., Hsieh, C., Hung, K., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.12.029 · Cited by 49
Bo, S., Castiglione, A., Ghigo, E., Gentile, L., Durazzo, M., Cavallo‐Perin, P., & Ciccone, G. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0299 · Cited by 43 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundHorsdal, H. T., Johnsen, S. P., Søndergaard, F. L., Jacobsen, J. B., Thomsen, R. W., Schmitz, O., Sørensen, H. T., & Rungby, J. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.971 · Cited by 40
Danchin, N., Charpentier, G., Ledru, F., Vaur, L., Guéret, P., Hanania, G., Blanchard, D., Lablanche, J., Genès, N., & Cambou, J. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.498 · Cited by 37
Pladevall, M., Riera‐Guàrdia, N., Margulis, A. V., Varas‐Lorenzo, C., Calingaert, B., & Perez‐Gutthann, S. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0187-5 · Cited by 36 · cited 1×
“In contrast to the RCTs, several observational studies have associated sulfonylureas with an increased risk of cardiovascular events anddeath (7).”
ResultAzoulay, L., Schneider‐Lindner, V., Dell’Aniello, S., Schiffrin, A., & Suissa, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1834 · Cited by 33 · cited 2×
“(29) Nested case-control Sulfonylureas vs.”
BackgroundSelf-citationCorrao, G., Romio, S., Zambon, A., Merlino, L. G., Bosi, E., & Scavini, M. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0939-6 · Cited by 32 · cited 3×
“comes, this exposure misclassification was magnified by using intent-to-treat (ITT) analyses (17,36,42).”
BackgroundMethodJuurlink, D. N., Gomes, T., Shah, B. R., & Mamdani, M. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03772.x · Cited by 32
Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study
Claesen, M., Gillard, P., Smet, F. D., Callens, M., Moor, B. D., & Mathieu, C. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3184 · Cited by 31 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundKoro, C. E., Bowlin, S. J., & Weiss, S. R. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1069 · Cited by 30 · cited 14×
“Overall, compared with sulfonylureamonotherapy, the combination of metformin with sulfonylureas was associated with an increased risk of CHF (odds ratio 1.38 [95% CI 1.13–1.69]).”
BackgroundResultInfluentialAndersson, C., Gislason, G., Jørgensen, C. H., Hansen, P. R., Vaag, A. A., Sørensen, R., Mérie, C., Olesen, J. B., Weeke, P. E., Schmiegelow, M., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.07.011 · Cited by 28
Ghotbi, A. A., Køber, L., Finer, N., James, W. P. T., Sharma, A. M., Caterson, I. D., Coutinho, W. F., Gaal, L. F. V., Torp-Pedersen, C. T., & Andersson, C. (2013) · Diabetes Care · doi:10.2337/dc13-0027 · Cited by 28 · cited 2×
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundSADIKOT, S. M., & Mogensen, C. E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.004 · Cited by 27
Horsdal, H. T., Søndergaard, F. L., Johnsen, S. P., & Rungby, J. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2097 · Cited by 26 · cited 2×
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundPantalone, K. M., Kattan, M. W., Cheng, Y., Wells, B. J., Arrigain, S., Nutter, B., Jain, A., Atreja, A., & Zimmerman, R. S. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03577.x · Cited by 26 · cited 1×
“Of those, 15 studies assessed outcomes within selected populations with cardiovascular complications (8,15,16,23,24,27,30–33,35,40,41,44,49), 6 studies performed within-class comparisons (9,19,28,34,39,47), and 4 studies used patients without type 2 diabetes as comparators (10,18,50,51).”
BackgroundGiorda, C. B., Picariello, R., Tartaglino, B., Marafetti, L., Noi, F. D., Alessiato, A., Costa, G., & Gnavi, R. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007959 · Cited by 26
Chang, C., Chang, Y., Lin, J., Caffrey, J. L., Wu, L., Lai, M., & Chuang, L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.125 · Cited by 25
Horsdal, H. T., Johnsen, S. P., Søndergaard, F. L., & Rungby, J. (2008) · Diabetologia · doi:10.1007/s00125-008-0947-6 · Cited by 24
Jørgensen, C. H., Gislason, G., Bretler, D., Sørensen, R., Norgaard, M. L., Hansen, M. L., Schramm, T. K., Abildstrom, S. Z., Torp-Pedersen, C. T., & Hansen, P. R. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.07.027 · Cited by 23
Wang, S.-H., Chen, D., Lin, Y., Mao, C., Tsai, M., Hsieh, M., Chou, C., Wen, M., Wang, C., Hsieh, I.-C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131122 · Cited by 21
Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
Nagendran, J., Oudit, G. Y., Bakal, J. A., Light, P. E., Dyck, J. R. B., & McAlister, F. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12126 · Cited by 16
Cited by
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
“For example, sulfonylureas which are the second most commonly used antidiabetic drug after metformin, have been shown to be associated with an increased risk of cardiovascular events and mortality [71].”
BackgroundRSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“Further, sulfonylureas and meglitinides increase the risk of myocardial ischemic injury and may be associated with increased risk of cardiovascular events and mortality.[808] SGLT-2 inhibitors are associated with high risks for DKA and volume depletion.”
BackgroundDouros, A., Dell’Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., & Suissa, S. (2018) · BMJ · doi:10.1136/bmj.k2693 · Cited by 135
Self-citationGenetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
Goodarzi, M. O., & Rotter, J. I. (2020) · Circulation Research · doi:10.1161/circresaha.119.316065 · Cited by 141
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Metadata
- Authors
- Azoulay, L., & Suissa, S.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Azoulay, Laurent
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-04-12
- Volume
- 40
- Issue
- 5
- Pages
- 706-714
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2607457744
- Cited by
- 195
- References
- 75
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 17 · 2023: 17 · 2022: 18 · 2021: 27 · 2020: 34 · 2019: 25 · 2018: 26 · 2017: 10
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- sulfonylureas, cardiovascular events, mortality, metformin, bias in observational studies, antidiabetic drugs, cardiovascular safety, type 2 diabetes
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Regression Analysis, Risk Factors, Sulfonylurea Compounds, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.